Myung In Pharmaceutical LTD. (KRX:317450)

South Korea flag South Korea · Delayed Price · Currency is KRW
67,500
-1,800 (-2.60%)
At close: Nov 25, 2025
Market Cap1.07T
Revenue (ttm)283.31B
Net Income (ttm)72.18B
Shares Out14.60M
EPS (ttm)6,407.02
PE Ratio11.49
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume70,607
Average Volume204,369
Open69,900
Previous Close69,300
Day's Range67,500 - 70,500
52-Week Range66,850 - 134,500
Betan/a
RSI29.00
Earnings DateMar 31, 2026

About KRX:317450

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate... [Read more]

Industry Pharmaceutical Preparations
Founded 1985
Employees 335
Stock Exchange Korea Stock Exchange
Ticker Symbol 317450
Full Company Profile

Financial Performance

In 2024, KRX:317450's revenue was 269.43 billion, an increase of 11.18% compared to the previous year's 242.34 billion. Earnings were 68.67 billion, a decrease of -7.84%.

Financial Statements

News

There is no news available yet.